Registration - In-house Corporation

Boehringer Ingelheim Canada Ltd. / Mark Lewis, President and CEO

Registration Information

In-house Corporation name: Boehringer Ingelheim Canada Ltd.
Responsible Officer Name: Mark Lewis, President and CEO
Responsible Officer Change History
Initial registration start date: 2022-05-30
Registration status: Active
Registration Number: 955680-371995

Associated Communications

Total Number of Communication Reports: 14

Monthly communication reports in the last 6 months: 3

Version 2 of 4 (2022-06-24 to 2023-06-01)

Registration versions:

Version 2 of 4 (2022-06-24 to 2023-06-01)

Lobbying Information

Subject Matters

Aboriginal Affairs
Economic Development
Health
Industry
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Policies or Program

Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).

Communication Techniques

Written communication
Oral communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)

In-house Corporation Details

Description of activities

One of the world's leading research-driven pharmaceutical companies.

Responsible officer name and position during the period of this registration

Andrea Sambati, President, CEO

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
5180 South Service Road
Burlington, ON L7L 5H4
Canada

Telephone number: 289-208-7527

Parent Company Information

Boehringer Ingelheim Canada Ltd. is not a subsidiary of any other parent companies.

Subsidiary Beneficiary Information

Boehringer Ingelheim Canada Ltd. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Andrea Sambati, President, CEO | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Mehmood Alibhai, Director of Patient Access & Healthcare Policy | No public offices held
Annie Beauchemin, Head, Market Access | No public offices held
Eve Blanchet, Regional Manager/ QUE, Patient Access and Health Policy | No public offices held
Gerald McCarron, Manager, External & Healthcare Affairs | No public offices held
Andrew Ransom, Manager, Patient Access | No public offices held

Boehringer Ingelheim Canada Ltd./

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Boehringer Ingelheim Canada Ltd./	2022-05-30	current

Boehringer Ingelheim Canada Ltd.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Mark Lewis	2023-08-15	Current
Ruta Stauskas	2023-06-01	2023-08-15
Andrea Sambati	2022-05-30	2023-06-01

Mark Lewis, President and CEO (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15^th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-14 of 14

Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joanna Lam, Policy and Regional Affairs Advisor | Indigenous Services Canada (ISC)
Subject Matter of the communication: Health
Communication date: 2023-10-04
Posted date: 2023-11-15
Communication number: 371995-579255 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dr. Stephen Ellis, MP | House of Commons
Subject Matter of the communication: Health
Communication date: 2023-08-03
Posted date: 2023-09-15
Communication number: 371995-574519 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel Saad, Senior Policy Advisor | Policy and Cabinet Affairs | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2023-06-29
Posted date: 2023-08-14
Communication number: 371995-574516 (amended from 371995-571382) View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel macdonald, Director General, Drugs for Rare Diseases | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-05-17
Posted date: 2023-06-15
Communication number: 371995-570188 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kasondra White, Director, Biomanufacturing Branch, Strategy Directorate | Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson, Director General, Life Sciences and Biomanufacturing Branch | Innovation, Science and Economic Development Canada (ISED)
- Eric Costen , Senior ADM, Industry Sector | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Science and Technology
Communication date: 2023-03-10
Posted date: 2023-04-15
Communication number: 371995-559405 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel MacDonald, Director General, Drugs for Rare Diseases | Health Canada (HC)
- Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies | Health Canada (HC)
- Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-12-06
Posted date: 2023-01-13
Communication number: 371995-553706 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Health Canada (HC)
- Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-10-05
Posted date: 2022-10-12
Communication number: 371995-543118 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Zachary Nixon, Senior Assistant, Stakeholder Relations & Regional Affairs | Global Affairs Canada (GAC)
Subject Matter of the communication: Health
Communication date: 2022-10-03
Posted date: 2022-10-12
Communication number: 371995-543110 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director | Office of Pharmaceutical Management Strategies | Health Canada (HC)
- Zachary Nixon, Senior Special Assistant Stakeholder Relations and Regional Affairs | Global Affairs Canada (GAC)
Subject Matter of the communication: Health
Communication date: 2022-09-13
Posted date: 2022-09-15
Communication number: 371995-541920 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-07-15
Posted date: 2022-08-04
Communication number: 371995-539058 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dr. Stephen Ellis, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2022-07-11
Posted date: 2022-08-04
Communication number: 371995-539059 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Yves Duclos, Minister of Health | Health Canada (HC)
- Adam Van Koeverden, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2022-07-11
Posted date: 2022-08-04
Communication number: 371995-539057 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)
- Dr. Stephen Ellis, Member of Parliament | House of Commons
- Adam Van Koeverden, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2022-05-31
Posted date: 2022-06-28
Communication number: 371995-536368 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Fast, Member of Parliament | House of Commons
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-05-30
Posted date: 2022-06-28
Communication number: 371995-536375 View associated registration

Mark Lewis, President and CEO (Corporation)

Learn more...

Results below are sorted by posted date, beginning with the most recent.

Results 1-14 of 14

Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joanna Lam, Policy and Regional Affairs Advisor | Indigenous Services Canada (ISC)
Subject Matter of the communication: Health
Communication date: 2023-10-04
Posted date: 2023-11-15
Communication number: 371995-579255 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dr. Stephen Ellis, MP | House of Commons
Subject Matter of the communication: Health
Communication date: 2023-08-03
Posted date: 2023-09-15
Communication number: 371995-574519 View associated registration
Boehringer Ingelheim Canada Ltd.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel Saad, Senior Policy Advisor | Policy and Cabinet Affairs | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2023-06-29
Posted date: 2023-08-14
Communication number: 371995-574516 (amended from 371995-571382) View associated registration

Date Modified:: 2023-11-27

Search and menus

Language selection

Registration - In-house Corporation

Boehringer Ingelheim Canada Ltd. / Mark Lewis, President and CEO

Registration Information

Associated Communications

Version 2 of 4 (2022-06-24 to 2023-06-01)

Version 2 of 4 (2022-06-24 to 2023-06-01)

Subject Matters

Subject Matter Details

Policies or Program

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties